StageIPO | IPO
Date of IPO5/5/2021
About Entheon Biomedical
Entheon Biomedical is a biotechnology company committed to the development of safe and effective psychedelic medicines in order to provide patients with access to evidence-based treatments for addiction disorders. On July 2nd, 2020, Entheon Biomedical was acquired by MPV Exploration. Terms of the transaction were not disclosed.
Missing: Entheon Biomedical's Product Demo & Case Studies
Promote your product offering to tech buyers.
Reach 1000s of buyers who use CB Insights to identify vendors, demo products, and make purchasing decisions.
Missing: Entheon Biomedical's Product & Differentiators
Don’t let your products get skipped. Buyers use our vendor rankings to shortlist companies and drive requests for proposals (RFPs).
Expert Collections containing Entheon Biomedical
Expert Collections are analyst-curated lists that highlight the companies you need to know in the most important technology spaces.
Entheon Biomedical is included in 1 Expert Collection, including Psychedelics.
Latest Entheon Biomedical News
Jan 13, 2023
Major Players Hikma Pharmaceuticals PLC, COMPASS, Verrian, Pfizer Inc., F. Hoffmann-La Roche Ltd., Jazz Pharmaceuticals Inc., PharmaTher Inc., Avadel, NeuroRx, Inc., Celon Pharma S.A., Red Light Holland, usonainstitute.org, Celon Pharma S.A., Entheon Biomedical, Novamind, Neonmind Biosciences among others Segmentation Analysis Gamma Hydroxybutyric Acid (GHB) are expected to be the fastest-growing segment in 2022. The drug type segment is Phencyclidine, Etamine, 3,4-MethylEnedioxyMethamphetamine (Ecstasy), Lysergic Acid Diethylamide (LSD), Gamma Hydroxybutyric Acid (GHB), Ayahuasca, Salvia, Psilocybin, and Others. The Gamma Hydroxybutyric Acid (GHB) segment is expected to witness the highest growth rate during the forecast period. As Xyrem from Jazz Pharmaceutical is one of the oldest psychedelic drugs on the market, with a sizable percentage of the market, and belongs to the drug class, the gamma-hydroxybutyric acid sector will be the most well-liked. It is a Schedule III restricted substance; therefore, a doctor must prescribe it and strictly supervise its use. GHB is used to treat excessive daytime drowsiness in its prescription form. In a small number of individuals, gamma-hydroxybutyric acid is also used to treat alcoholism and drug withdrawal. GHB is used to treat narcolepsy and, less frequently, alcoholism medically, but it is not yet known how effective it is compared to other pharmacotherapies for alcoholism. Fibromyalgia is occasionally treated with it off-label. Narcolepsy is expected to be the fastest-growing segment in 2022. The patient type segment is resistant depression, major depressive disorder, post-traumatic stress disorder, panic disorder, narcolepsy, opiate addiction, and others. The narcolepsy segment is expected to witness the highest growth rate during the forecast period. Pharmaceuticals, which is the market's biggest investor and is used to treat the illness. Daytime fatigue and sleep episodes are hallmarks of the chronic sleep condition narcolepsy. Narcoleptics have trouble staying up for extended periods of time under any circumstance. Numerous problems might arise in your daily life if you have narcolepsy. Despite the fact that narcolepsy is not a fatal condition, it can cause mishaps, injuries, and even situations when life is in danger. Due to episodes of extreme daytime drowsiness, people with narcolepsy may find it difficult to maintain relationships, do well in school, or hold their jobs. Regional Analysis The regional analysis provides a detailed perception of the key regions and the countries. Some of the key countries analyzed for the psychedelic drugs market include the US, Canada, Mexico, Germany, France, the U.K., Italy, Spain, Russia, China, Japan, India, Brazil, Peru, UAE, South Africa, and Saudi Arabia. The North American region witnessed a major share. because of the region's developments in psychedelics, legislative changes, and the rising prevalence of mental illnesses like depression. Additionally, it is predicted that changing viewpoints, less severe drug side effects, and cost-effectiveness would propel market expansion. Due to strong demand in North America, it is anticipated that the psychedelic drugs market would expand. The market is nevertheless confronted with several difficulties, including the ambiguity surrounding FDA clearance, the early stages of the psychedelics industry's development, the stigma attached to the use of psychedelic drugs, and so on. Country Analysis Germany Germany's psychedelic drugs market size was valued at USD 20.1 million in 2022 and is expected to reach USD 25.3 million by 2030, at a CAGR of 2.9% from 2023 to 2030. The enormous potential for income creation is due to regulators' recent willingness to support and embrace novel methods for studying the therapeutic effects of psychedelic substances. China China’s psychedelic drugs market size was valued at USD 32.7 million in 2022 and is expected to reach USD 44.4 million by 2030, at a CAGR of 3.9% from 2023 to 2030. This is a result of the high frequency of mental diseases in the region, and the market is being helped by quick research and development. India India's psychedelic drugs market size was valued at USD 29.4 million in 2022 and is expected to reach USD 38.7 million by 2030, at a CAGR of 3.5% from 2023 to 2030. Depression and other mental problems have grown as illegal drug use has increased. Thus, as depression and other mental diseases are becoming more common, so is the need for psychedelic substances, which is predicted to fuel market expansion in the region. Covid-19 Impact Covid-19 had a major impact on almost all industries, such as electronics, semiconductors, manufacturing, automobile, etc. However, several companies operating in the technology sector have seen increased revenue due to significant changes in consumer preferences toward technological services. In addition, the pandemic has led to significant growth in technology across developing and developed countries. Furthermore, the growth of this market is mainly driven owing to the increase in growing awareness and the tendency to seek new medications are propelling the growth of the market across the countries. Buy Now Full Report @ https://greyviews.com/checkout/379/single_user_license Contact Us
Entheon Biomedical Frequently Asked Questions (FAQ)
When was Entheon Biomedical founded?
Entheon Biomedical was founded in 2019.
Where is Entheon Biomedical's headquarters?
Entheon Biomedical's headquarters is located at 3694 Marine Avenue, Port Moody.
What is Entheon Biomedical's latest funding round?
Entheon Biomedical's latest funding round is IPO.
How much did Entheon Biomedical raise?
Entheon Biomedical raised a total of $80K.
Who are the investors of Entheon Biomedical?
Investors of Entheon Biomedical include MPV Exploration.
Discover the right solution for your team
The CB Insights tech market intelligence platform analyzes millions of data points on vendors, products, partnerships, and patents to help your team find their next technology solution.